Lipocine Shares Plumb New Lows After Postpartum Depression Study Failure

Dow Jones

04/02

By Colin Kellaher

Lipocine shares collapsed Thursday after the biopharmaceutical company's LPCN 1154 drug candidate failed in a late-stage study in postpartum depression.

Shares of the Salt Lake City, Utah, company were recently changing hands at $1.94, down 79%, after touching an all-time low of $1.81 earlier in the session.

Lipocine said LPCN 1154 missed the primary endpoint of the Phase 3 study, failing to show a statistically significant reduction in a key measure of the severity of depression compared with placebo at hour 60.

Lipocine said it plans to preserve capital and evaluate all options available to the company going forward.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

April 02, 2026 10:02 ET (14:02 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2624502198"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2624502198\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2624502198?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-02 22:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2624502198","market":"sh","top_or_hot":-1,"title":"Lipocine Shares Plumb New Lows After Postpartum Depression Study Failure","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Lipocine shares collapsed Thursday after the biopharmaceutical company's LPCN 1154 drug candidate failed in a late-stage study in postpartum depression. \n</p>\n<p>\n  Shares of the Salt Lake City, Utah, company were recently changing hands at $1.94, down 79%, after touching an all-time low of $1.81 earlier in the session. \n</p>\n<p>\n  Lipocine said LPCN 1154 missed the primary endpoint of the Phase 3 study, failing to show a statistically significant reduction in a key measure of the severity of depression compared with placebo at hour 60. \n</p>\n<p>\n  Lipocine said it plans to preserve capital and evaluate all options available to the company going forward. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2026 10:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lipocine Shares Plumb New Lows After Postpartum Depression Study Failure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLipocine Shares Plumb New Lows After Postpartum Depression Study Failure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-04-02 22:02</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Colin Kellaher \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Lipocine shares collapsed Thursday after the biopharmaceutical company's LPCN 1154 drug candidate failed in a late-stage study in postpartum depression. \n</p>\n<p>\n  Shares of the Salt Lake City, Utah, company were recently changing hands at $1.94, down 79%, after touching an all-time low of $1.81 earlier in the session. \n</p>\n<p>\n  Lipocine said LPCN 1154 missed the primary endpoint of the Phase 3 study, failing to show a statistically significant reduction in a key measure of the severity of depression compared with placebo at hour 60. \n</p>\n<p>\n  Lipocine said it plans to preserve capital and evaluate all options available to the company going forward. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 02, 2026 10:02 ET (14:02 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2624502198","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2624502198","pubTimestamp":1775138520,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Lipocine shares collapsed Thursday after the biopharmaceutical company's LPCN 1154 drug candidate failed in a late-stage study in postpartum depression.Shares of the Salt Lake City, Utah, company were recently changing hands at $1.94, down 79%, after touching an all-time low of $1.81 earlier in the session.Lipocine said LPCN 1154 missed the primary endpoint of the Phase 3 study, failing to show a statistically significant reduction in a key measure of the severity of depression compared with placebo at hour 60.Lipocine said it plans to preserve capital and evaluate all options available to the company going forward.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","LPCN":"Lipocine Inc"},"translate_title":"产后抑郁症研究失败后，Lipocine股价跌至新低","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LPCN":1.5},"content_text":"By Colin Kellaher \n\n\n \n\n\n  Lipocine shares collapsed Thursday after the biopharmaceutical company's LPCN 1154 drug candidate failed in a late-stage study in postpartum depression. \n\n\n  Shares of the Salt Lake City, Utah, company were recently changing hands at $1.94, down 79%, after touching an all-time low of $1.81 earlier in the session. \n\n\n  Lipocine said LPCN 1154 missed the primary endpoint of the Phase 3 study, failing to show a statistically significant reduction in a key measure of the severity of depression compared with placebo at hour 60. \n\n\n  Lipocine said it plans to preserve capital and evaluate all options available to the company going forward. \n\n\n \n\n\n  Write to Colin Kellaher at colin.kellaher@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 02, 2026 10:02 ET (14:02 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-2","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}